Objectives: To clarify the effects of dutasteride on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement. Methods: The present prospective study was carried out in 110 symptomatic benign prostatic enlargement patients treated with daily administration of 0.5 mg dutasteride. We analyzed serum hormonal levels and aging related symptoms using a validated Aging Male Symptom questionnaire at baseline and after 3 months of dutasteride treatment. Results: The mean total testosterone, free testosterone and luteinizing hormone levels after dutasteride treatment were approximately 20% higher than those at baseline. The percentage increases in total and free testosterone levels were negatively correlated with these baseline levels. Baseline age, levels of total testosterone and free testosterone, and the changes in the rate of luteinizing hormone after dutasteride treatment tended to be correlated with an increase in the rate of total testosterone and free testosterone after dutasteride treatment. In a subgroup of 26 patients with moderate-to-severe aging male symptoms, poor morning erection and free testosterone levels <8.5 pg/mL, total aging male symptoms, and somatic symptoms scores significantly decreased after dutasteride treatment with an increase of total and free testosterone. Conclusions: The increase of endogenous free testosterone and total testosterone by dutasteride might bring additional benefits of improvement of aging male-related symptoms, especially in patients with lower free testosterone baseline levels and moderate-to-poor aging-related symptoms.
Introduction
Testosterone, one of the main androgens, requires conversion to DHT by 5-alpha reductase for its action on prostate enlargement. 1 In moderate and severe LUTS and BPH patients, administration of a 5-ARI, such as DUT, is an appropriate and effective treatment option 2 that decreases serum and intraprostatic DHT levels, 3 and results in the reduction of prostate size, prevention of BPH progression and reduced urinary retention, and the need for BPH-related surgery. 4 Androgens also have significant biological effects, and are associated with sexual differentiation, growth of the external genitalia, 5 risk of bone fracture 6 and decrease of fat mass. 7 However, serum TT and FT decline with age, and this decline is sometimes thought to cause LOH syndrome. 8 In LOH patients, TRT leads to substantial improvements in muscle strength, fat-free mass 9 and BMD. 10 In contrast, some reports show that 5-ARI induced the elevation of serum TT and FT, 11, 12 and these changes caused secondary effects of decreased BMI 11 and increased BMD. 12 Hypogonadism and LUTS associated with BPE are common disorders in elderly men. 13, 14 However, few studies have evaluated the influence of changes in hormone levels by 5-ARI administration on hypogonadism symptoms in BPE patients. Therefore, we investigated (i) hormonal changes after DUT treatment; and (ii) the direct association between changes in hormones and LOH symptoms using one of the most widely used questionnaires, the AMS scale.
Methods Patients
The present prospective study was carried out in 110 patients treated with 0.5 mg DUT for symptomatic BPE from 2009 to 2012 at Keio University Hospital, Tokyo, Japan. Symptomatic BPE consisted of both moderate-to-severe LUTS (IPSS ≥8) and enlarged prostate size (total prostate volume ≥20 mL). These patients did not include those with previous histories of prostate cancer or previous treatment with 5-ARI (finasteride or DUT), testosterone or phosphodiesterase-5 inhibitor. During the study period, patients were not treated with any additional medication, such as an anti-muscarinic drugs and alpha-blockers.
Evaluations
IPSS, OABSS, AMS questionnaires and serum hormones, including TT, FT, LH, FSH PRL, were measured at baseline, and after 3 months of DUT treatment. The AMS was developed to assess aging male-related symptoms, and is a selfanswer-type questionnaire of 17 items, including five psychological symptoms score items (questions 6-8, 11 and 13), seven somatic symptoms score items (questions 1-5, 9 and 10) and five sexual symptoms score items (questions 12 and 14-17). 15 Each item is evaluated with five phases, from 1 point (no symptoms) to 5 points (very severe symptoms). The total score is the sum of the scores of each item (range of scores 17-85). Severity is classified into four groups based on the range of scores: 17-26 points, no/low symptoms; 27-36 points, mild symptoms; 37-49 points, moderate symptoms; and 50-85 points, severe symptoms. 16 We extracted the subgroup of 26 patients who had an AMS score >37 points (moderate-to-severe in AMS criteria), poor morning erection (≥4 points in AMS question 16), serum FT levels <8.5 pg/mL at baseline and were defined as symptomatic hypogonadism patients. We also analyzed the clinical dates in this cohort after DUT treatment.
The present prospective study was approved by the ethical review board of our institution (Keio University School of Medicine Ethical Review Board 2009-297), and all patients provided written informed consent. Information regarding the present study was registered on the University Hospital Medical Information Network in Japan (registration number: UMIN000003573) before the study initiation. This study was carried out according to the Helsinki Declaration and ethical guidelines about clinical studies.
Blood sampling tests: TT, FT, LH, FSH and PRL
Blood samples were collected from each patient in the morning (08.00-10.00 hours) at baseline and after 3 months of DUT treatment. Serum TT and FT levels were measured by radioimmunology assay using a Diagnostic Products Corporation/TT kit and FT kit (Mitsubishi Chemical Yatoron, Tokyo, Japan), and FSH, LH and PRL levels were measured using a SPAC-S kit (SRL, Tokyo, Japan).
Statistical analysis
Results are presented as mean values plus or minus SD. Differences in serum hormone level, IPSS, OABSS and AMS scores between baseline and 3 months after DUT administration were analyzed using the Wilcoxon signed-rank test. The factors that correlated with the increased ratios of TT and FT after 3 months of DUT treatment were analyzed by multiple linear regression analysis. Correlation between baseline levels of TT and FT and the increased rates after 3 months of DUT treatment were analyzed using Spearman's rank correlation test. Values of P < 0.05 were considered significant. These analyses were carried out using JMP version 10.0.2 statistical software package (SAS Institute, Cary, NC, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA).
Results

IPSS, OABSS and AMS at baseline, and after 3 months of DUT treatment
The mean age in the 110 patients was 71.3 AE 7.8 years. Just before DUT treatment, the mean prostate volume and serum PSA level were 48.7 AE 24.2 mL and 4.3 AE 3.8 ng/mL, respectively. The mean total IPSS and OABSS in overall patients after 3 months of DUT treatment were 13.6 AE 6.9 and 5.1 AE 2.7, respectively, which were significantly lower than those at baseline (Table 1) . At baseline, AMS scores of 17-26 points, 27-36 points, 37-49 points, and >49 points were seen in 21 (19.1%), 50 (45.5%), 27 (24.5%) and 12 (10.9%) patients, respectively. The mean total AMS score, psychological symptoms score, and somatic symptoms score in overall patients after 3 months of DUT treatment were 35.5, 7.2 and 13.7, which were not significantly different compared with those at baseline. In contrast, the sexual symptoms score in overall patients after 3 months of DUT treatment was 14.6, which was significantly higher than at baseline. 
Changes in serum hormones after DUT treatment
The mean TT, FT, and LH levels in overall patients after 3 months of DUT treatment were 4.56 ng/mL, 8.9 pg/mL and 9.4 mIU/mL, respectively, which were significantly higher than those at baseline (4.00 ng/mL, 7.7 pg/mL and 8.7 mIU/mL; Table 1 ), and the mean percent increases in TT, FT, and LH were 16.8%, 20.4% and 18.5%, respectively. In contrast, mean FSH and PRL levels after 3 months of DUT treatment were 15.7 mIU/mL and 8.5 ng/mL, which were not significantly different compared with those at baseline (15.6 mIU/mL and 8.5 ng/mL, respectively; Table 1 ). There were significant negative correlations between the baseline levels of serum TT (correlation coefficient À0.368, P < 0.001; Fig. 1a ) and FT (correlation coefficient À0.378, P < 0.001; Fig. 1b) and their percentage increases after DUT treatment. Multiple linear regression analysis showed that the baseline age, TT level and percentage increase in LH after DUT treatment were correlated with the percentage increase in TT after 3 months of DUT treatment (P = 0.011, 0.005 and 0.045, respectively; Table 2 ). The percentage increase in FT after 3 months of DUT treatment was significantly correlated with the baseline age and FT level (P = 0.008 and P < 0.001, respectively; Table 3 ), and tended to be correlated with percentage increase in LH (P = 0.068).
Changes in IPSS, OABSS and AMS after DUT treatment in patients with symptomatic hypogonadism
In a subgroup of 26 patients with symptomatic hypogonadism, mean TT and FT levels significantly increased from 3.98 to 4.27 ng/mL (P = 0.029) and from 6.5 to 7.3 pg/mL (P = 0.032), respectively (Table 4) . Of them, the increases in TT and FT were 17.1% and 25.9% in eight patients with an AMS improvement of ≥6 points, 8.0% and 14.8% in eight patients with an AMS improvement of 3-5 points, and À1.7% and 1.7% in 10 patients with an AMS improvement of <3 points. Mean IPSS score, total AMS score, and AMS subdomain score of somatic symptoms score significantly decreased from 18.0 to 14.3 (P = 0.040), from 47.7 to 43.0 (P = 0.017) and from 18.9 to 16.7 (P = 0.002), respectively. Meanwhile, in a subgroup of 84 patients without symptomatic hypogonadism, mean TT and FT levels also significantly increased from 4.01 to 4.65 ng/mL (P < 0.001) and from 8.1 to 9.4 pg/mL (P < 0.001), whereas mean IPSS score significantly decreased from 16.7 to 13.4 (P < 0.001), but mean AMS total score and AMS subdomain score of sexual symptoms score significantly increased from 30.9 to 33.2 (P = 0.008) and from 12.4 to 14.0 (P < 0.001), respectively.
Discussion
The present results showed that daily administration of 0.5 mg DUT resulted in significant increases in serum TT, FT and LH levels in our cohort of symptomatic BPE patients. Multivariate analysis showed that baseline age, levels of TT and FT, and the percentage increase in LH after DUT treatment were significantly correlated with the percentage increase in TT and FT after DUT treatment. Overall, DUT treatment did not improve the AMS score, but it significantly decreased both the total AMS score and somatic symptoms score with the increase of TT and FT level in a subgroup of patients with poor morning erection, serum FT level < 8.5 pg/mL and moderate-to-severe AMS score at the beginning of DUT treatment.
The present results confirmed the previous findings of a maximum increase in serum TT and FT levels after 5-ARI treatment in patients with the lowest TT level at baseline, but few studies have evaluated the relationship between TT and FT and other hormonal changes after 5-ARI treatment. 11, 17 Amory et al. showed that serum LH, FSH and estradiol did not significantly change after 5-ARI treatment in a small number of healthy men aged 18-55 years. 18 In contrast, the present study found that the serum LH level was elevated by DUT treatment, and the percentage increase in LH tended to be associated with the percentage increases in TT and FT levels using multiple linear regression analysis. A possible explanation for the LH increase after DUT treatment is that prostate tissue contains the LH receptor, and a decrease of this receptor by shrinkage of BPH with DUT treatment might induce a negative feedback to the hypothalamic-pituitary axis. 19, 20 Furthermore, from the finding that DUT treatment results in suppression of not only prostatic DHT levels but also serum DHT levels by 90% or more, we assume that a strong suppression of serum DHT by DUT treatment induced a reciprocal increase in the hypothalamic-pituitary axis, and contributed to the increases in serum TT and FT. 3 Shigehara et al. found that DUT treatment improved BMD accompanied by increased TT and FT levels in patients with low baseline serum TT and FT levels. 12 The present results also showed DUT treatment has a positive impact on the AMS score accompanied by increased TT and FT levels, especially in BPE patients with lower FT levels at baseline and moderate to poor aging-related symptoms. To the best of our knowledge, this is the first study to evaluate changes in aging-related symptoms using the AMS questionnaire after DUT treatment in symptomatic BPE patients.
The AMS is a widely used questionnaire for evaluating the baseline status of patients with LOH syndrome in Japan, and it can assess the therapeutic effect of TRT in these patients. 21 TRT can improve the age-related symptoms associated with muscle strength 22 and BMD, 10 and might improve overall physical performance. One of the possible explanations for the positive influence on the AMS score by DUT treatment might be due to reciprocal elevation of TT and estrogen by aromatase despite strong suppression of DHT, because testosterone directly binds the AR and has a more important role than DHT in target tissues where 5-alpha reductase is expressed less, though DHT has 2-10-fold higher affinity with AR than testosterone. 23 A previous study has shown that plasma levels of estradiol, which plays a major role in metabolic processes, mood and cognition, 23 were increased by 5-ARI treatment. 24 Furthermore, combined treatment of TRT with concomitant 5-ARI has resulted in marked increases in serum T concentration, 25 and a reduction of prostate volume and prostate-specific antigen in hypogonadal men. 26 Further study to determine whether TRT with 5-ARI therapy could provide a dramatic improvement of androgen-dependent symptoms in LOH patients is warranted.
There were several limitations to the present study. First, our study was carried out prospectively, but the number of patients was not so large. Second, patients with serum TT or FT below the lower limit of normal levels do not necessarily show symptomatic hypogonadism. 27 Indeed, 73 of 110 (66.3%) patients showed levels below the lower limit of normal FT levels for reference value in Japanese LOH syndrome guidelines, but just 39 of 110 (35.5%) patients showed moderate-to-severe AMS scores before DUT treatment in the present study. 28 Therefore, we used not only lower FT level, but also poor morning erection 29 and having moderate-to-severe total AMS scores for defining so-called "symptomatic hypogonadism" in our present study. Third, the exact hormonal concentrations were not measured using methods such as liquid chromatography-mass spectrometry, as the method is not practical in daily clinical use. In conclusion, DUT treatment in men with BPE led to significant increases in serum FT, TT and LH levels. Significant clinical improvement of AMS scores after DUT treatment with increased serum FT and TT levels were observed in patients with lower FT levels and moderate-to-poor AMS scores accompanied by poor morning erections at baseline. These results suggest that the increases in endogenous FT and TT levels by DUT might have additional benefits of improvement of aging male-related symptoms, apart from the improvement of urinary symptoms, especially in BPE patients with lower FT levels at baseline and moderate-to-poor aging-related symptoms.
